|Bid||1.1000 x 334700|
|Ask||1.1650 x 1317400|
|Day's range||1.0900 - 1.1400|
|52-week range||1.0900 - 2.5200|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||N/A|
|Earnings date||25 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||25 Mar 1988|
|1y target est||N/A|
A look at the shareholders of Starpharma Holdings Limited ( ASX:SPL ) can tell us which group is most powerful. Large...
Australian biotech company Starpharma today announced it has signed a sales and distribution agreement for its VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. The Italian over-the-counter pharmaceutical market is the third largest in Europe after Germany and the UK.
DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma's DEP® cabazitaxel is a water soluble, polysorbate-80 free formulation, without requirement for pre-treatment with steroids nor G-CSF to reduce the risk of severe bone marrow toxicity.